Hodgkin's disease (HD)

A historical perspective

Sante Tura, Patrizio Mazza, Pier Luigi Zinzani, Franco Verlicchi, Michele Baccarani, Francesco Lauria, Mauro Fiacchini, Marco Gobbi, Giuseppe Bandini, Ermanno Emiliani, Ruggero Sciascia, Lucio Babini, Enza Barbieri, Stefano Neri, Vittorio Palmieri, Giuseppe Dominici, Eugenio Tonielli, Filippo Sommariva, Roberto Giardino, Bruno Cola & 2 others Filippo Gherlinzoni, Antonello Franchini

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Five hundred and seven patients with Hodgkin's lymphoma (HL), forming the basis of our 18 years experience, are retrospectively analyzed. Four therapeutic periods are recognizable: 1. 1. The 1966-1970 period was characterized by the absence of treatment and management policy. The 55 patients entered in this period experienced 70 and 56% survival at 5 and 10 yr, respectively, from diagnosis. 2. 2. The 1971-1974 period was characterized by the increasing knowledge of staging relevance and therapeutic approaches. The 153 patients who were treated in this period experienced 72 and 60% survival and 5 and 10 yr, respectively. 3. 3. The 1975-1980 period was characterized by a large combination of MOPP and radiotherapy. The 216 patients who entered this period observed 80 and 72.5% survival at 5 and 10 yr, respectively. 4. 4. The last therapeutic period (1980 to present time) is characterized by the increasing relevance of prognostic factors and alternating use of MOPP and ABVD as non-cross resistant regimen. The 83 patients who entered this period showed 90% survival at 5 yr. Both survival and disease-free survival were positively influenced by the change of therapeutic strategies during the four periods (P <0.005). Although better results have been recorded moving from one to the next therapeutic period, the present policy has been also based on the recognition of a high number of late complications due to the therapy. Preliminary results about the present therapeutic experience seem to indicate both a good remission rate and low incidence of complications.

Original languageEnglish
Pages (from-to)1315-1323
Number of pages9
JournalEuropean Journal of Cancer and Clinical Oncology
Volume22
Issue number11
DOIs
Publication statusPublished - 1986

Fingerprint

Hodgkin Disease
Survival
Therapeutics
Disease-Free Survival
Radiotherapy
Incidence

ASJC Scopus subject areas

  • Oncology

Cite this

Tura, S., Mazza, P., Zinzani, P. L., Verlicchi, F., Baccarani, M., Lauria, F., ... Franchini, A. (1986). Hodgkin's disease (HD): A historical perspective. European Journal of Cancer and Clinical Oncology, 22(11), 1315-1323. https://doi.org/10.1016/0277-5379(86)90139-2

Hodgkin's disease (HD) : A historical perspective. / Tura, Sante; Mazza, Patrizio; Zinzani, Pier Luigi; Verlicchi, Franco; Baccarani, Michele; Lauria, Francesco; Fiacchini, Mauro; Gobbi, Marco; Bandini, Giuseppe; Emiliani, Ermanno; Sciascia, Ruggero; Babini, Lucio; Barbieri, Enza; Neri, Stefano; Palmieri, Vittorio; Dominici, Giuseppe; Tonielli, Eugenio; Sommariva, Filippo; Giardino, Roberto; Cola, Bruno; Gherlinzoni, Filippo; Franchini, Antonello.

In: European Journal of Cancer and Clinical Oncology, Vol. 22, No. 11, 1986, p. 1315-1323.

Research output: Contribution to journalArticle

Tura, S, Mazza, P, Zinzani, PL, Verlicchi, F, Baccarani, M, Lauria, F, Fiacchini, M, Gobbi, M, Bandini, G, Emiliani, E, Sciascia, R, Babini, L, Barbieri, E, Neri, S, Palmieri, V, Dominici, G, Tonielli, E, Sommariva, F, Giardino, R, Cola, B, Gherlinzoni, F & Franchini, A 1986, 'Hodgkin's disease (HD): A historical perspective', European Journal of Cancer and Clinical Oncology, vol. 22, no. 11, pp. 1315-1323. https://doi.org/10.1016/0277-5379(86)90139-2
Tura S, Mazza P, Zinzani PL, Verlicchi F, Baccarani M, Lauria F et al. Hodgkin's disease (HD): A historical perspective. European Journal of Cancer and Clinical Oncology. 1986;22(11):1315-1323. https://doi.org/10.1016/0277-5379(86)90139-2
Tura, Sante ; Mazza, Patrizio ; Zinzani, Pier Luigi ; Verlicchi, Franco ; Baccarani, Michele ; Lauria, Francesco ; Fiacchini, Mauro ; Gobbi, Marco ; Bandini, Giuseppe ; Emiliani, Ermanno ; Sciascia, Ruggero ; Babini, Lucio ; Barbieri, Enza ; Neri, Stefano ; Palmieri, Vittorio ; Dominici, Giuseppe ; Tonielli, Eugenio ; Sommariva, Filippo ; Giardino, Roberto ; Cola, Bruno ; Gherlinzoni, Filippo ; Franchini, Antonello. / Hodgkin's disease (HD) : A historical perspective. In: European Journal of Cancer and Clinical Oncology. 1986 ; Vol. 22, No. 11. pp. 1315-1323.
@article{d83ac4179b1c4028b44053757a074481,
title = "Hodgkin's disease (HD): A historical perspective",
abstract = "Five hundred and seven patients with Hodgkin's lymphoma (HL), forming the basis of our 18 years experience, are retrospectively analyzed. Four therapeutic periods are recognizable: 1. 1. The 1966-1970 period was characterized by the absence of treatment and management policy. The 55 patients entered in this period experienced 70 and 56{\%} survival at 5 and 10 yr, respectively, from diagnosis. 2. 2. The 1971-1974 period was characterized by the increasing knowledge of staging relevance and therapeutic approaches. The 153 patients who were treated in this period experienced 72 and 60{\%} survival and 5 and 10 yr, respectively. 3. 3. The 1975-1980 period was characterized by a large combination of MOPP and radiotherapy. The 216 patients who entered this period observed 80 and 72.5{\%} survival at 5 and 10 yr, respectively. 4. 4. The last therapeutic period (1980 to present time) is characterized by the increasing relevance of prognostic factors and alternating use of MOPP and ABVD as non-cross resistant regimen. The 83 patients who entered this period showed 90{\%} survival at 5 yr. Both survival and disease-free survival were positively influenced by the change of therapeutic strategies during the four periods (P <0.005). Although better results have been recorded moving from one to the next therapeutic period, the present policy has been also based on the recognition of a high number of late complications due to the therapy. Preliminary results about the present therapeutic experience seem to indicate both a good remission rate and low incidence of complications.",
author = "Sante Tura and Patrizio Mazza and Zinzani, {Pier Luigi} and Franco Verlicchi and Michele Baccarani and Francesco Lauria and Mauro Fiacchini and Marco Gobbi and Giuseppe Bandini and Ermanno Emiliani and Ruggero Sciascia and Lucio Babini and Enza Barbieri and Stefano Neri and Vittorio Palmieri and Giuseppe Dominici and Eugenio Tonielli and Filippo Sommariva and Roberto Giardino and Bruno Cola and Filippo Gherlinzoni and Antonello Franchini",
year = "1986",
doi = "10.1016/0277-5379(86)90139-2",
language = "English",
volume = "22",
pages = "1315--1323",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",
number = "11",

}

TY - JOUR

T1 - Hodgkin's disease (HD)

T2 - A historical perspective

AU - Tura, Sante

AU - Mazza, Patrizio

AU - Zinzani, Pier Luigi

AU - Verlicchi, Franco

AU - Baccarani, Michele

AU - Lauria, Francesco

AU - Fiacchini, Mauro

AU - Gobbi, Marco

AU - Bandini, Giuseppe

AU - Emiliani, Ermanno

AU - Sciascia, Ruggero

AU - Babini, Lucio

AU - Barbieri, Enza

AU - Neri, Stefano

AU - Palmieri, Vittorio

AU - Dominici, Giuseppe

AU - Tonielli, Eugenio

AU - Sommariva, Filippo

AU - Giardino, Roberto

AU - Cola, Bruno

AU - Gherlinzoni, Filippo

AU - Franchini, Antonello

PY - 1986

Y1 - 1986

N2 - Five hundred and seven patients with Hodgkin's lymphoma (HL), forming the basis of our 18 years experience, are retrospectively analyzed. Four therapeutic periods are recognizable: 1. 1. The 1966-1970 period was characterized by the absence of treatment and management policy. The 55 patients entered in this period experienced 70 and 56% survival at 5 and 10 yr, respectively, from diagnosis. 2. 2. The 1971-1974 period was characterized by the increasing knowledge of staging relevance and therapeutic approaches. The 153 patients who were treated in this period experienced 72 and 60% survival and 5 and 10 yr, respectively. 3. 3. The 1975-1980 period was characterized by a large combination of MOPP and radiotherapy. The 216 patients who entered this period observed 80 and 72.5% survival at 5 and 10 yr, respectively. 4. 4. The last therapeutic period (1980 to present time) is characterized by the increasing relevance of prognostic factors and alternating use of MOPP and ABVD as non-cross resistant regimen. The 83 patients who entered this period showed 90% survival at 5 yr. Both survival and disease-free survival were positively influenced by the change of therapeutic strategies during the four periods (P <0.005). Although better results have been recorded moving from one to the next therapeutic period, the present policy has been also based on the recognition of a high number of late complications due to the therapy. Preliminary results about the present therapeutic experience seem to indicate both a good remission rate and low incidence of complications.

AB - Five hundred and seven patients with Hodgkin's lymphoma (HL), forming the basis of our 18 years experience, are retrospectively analyzed. Four therapeutic periods are recognizable: 1. 1. The 1966-1970 period was characterized by the absence of treatment and management policy. The 55 patients entered in this period experienced 70 and 56% survival at 5 and 10 yr, respectively, from diagnosis. 2. 2. The 1971-1974 period was characterized by the increasing knowledge of staging relevance and therapeutic approaches. The 153 patients who were treated in this period experienced 72 and 60% survival and 5 and 10 yr, respectively. 3. 3. The 1975-1980 period was characterized by a large combination of MOPP and radiotherapy. The 216 patients who entered this period observed 80 and 72.5% survival at 5 and 10 yr, respectively. 4. 4. The last therapeutic period (1980 to present time) is characterized by the increasing relevance of prognostic factors and alternating use of MOPP and ABVD as non-cross resistant regimen. The 83 patients who entered this period showed 90% survival at 5 yr. Both survival and disease-free survival were positively influenced by the change of therapeutic strategies during the four periods (P <0.005). Although better results have been recorded moving from one to the next therapeutic period, the present policy has been also based on the recognition of a high number of late complications due to the therapy. Preliminary results about the present therapeutic experience seem to indicate both a good remission rate and low incidence of complications.

UR - http://www.scopus.com/inward/record.url?scp=0023014053&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023014053&partnerID=8YFLogxK

U2 - 10.1016/0277-5379(86)90139-2

DO - 10.1016/0277-5379(86)90139-2

M3 - Article

VL - 22

SP - 1315

EP - 1323

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 11

ER -